Dive into the Details of Radionuclide Antibody Conjugates: What Role Do EPR Effects and LETs of Different Radionuclides Play?

Overview

Journal Am J Nucl Med Mol Imaging

Date 2024 Jan 11

PMID 38204607

Authors

Sixuan Cheng

Dawei Jiang

Mengting Li

Affiliations

Soon will be listed here.

Abstract

Radionuclide antibody conjugate (RAC) is a promising diagnostic and therapeutic tool. It combines radionuclides and antibodies by connecting arms and chelating agents, offering precise targeting and potent killing of tumor cells. However, further development and optimization of this radiopharmaceutical is needed to enhance the ultimate substantive efficacy for clinical translation. In this issue of AJNMMI, Strand et al. evaluated the enhanced permeability effect and different linear energy transfer (LET) of radionuclides in a prostate cancer xenograft model. The results showed that specific targeting might negatively influence normal organ uptake when targeting secreted antigens and different LETs of radionuclides might have diverse effects on receptor expression and cell proliferation in tumors. The findings provide new thinking for the development of antibody-based radiopharmaceuticals.

References

Yang Z, Li J, Wang Z, Dong D, Qi X . Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials. 2014; 35(19):5226-39. DOI: 10.1016/j.biomaterials.2014.03.017. View

Wei W, Rosenkrans Z, Liu J, Huang G, Luo Q, Cai W . ImmunoPET: Concept, Design, and Applications. Chem Rev. 2020; 120(8):3787-3851. PMC: 7265988. DOI: 10.1021/acs.chemrev.9b00738. View

Matsumura Y, Maeda H . A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46(12 Pt 1):6387-92. View

Murata T, Lin M, Aritake K, Matsumoto S, Narumiya S, Ozaki H . Role of prostaglandin D2 receptor DP as a suppressor of tumor hyperpermeability and angiogenesis in vivo. Proc Natl Acad Sci U S A. 2008; 105(50):20009-14. PMC: 2596745. DOI: 10.1073/pnas.0805171105. View

Pattipeiluhu R, Arias-Alpizar G, Basha G, Chan K, Bussmann J, Sharp T . Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System. Adv Mater. 2022; 34(16):e2201095. PMC: 9461706. DOI: 10.1002/adma.202201095. View

Kang H, Rho S, Stiles W, Hu S, Baek Y, Hwang D . Size-Dependent EPR Effect of Polymeric Nanoparticles on Tumor Targeting. Adv Healthc Mater. 2019; 9(1):e1901223. PMC: 7224408. DOI: 10.1002/adhm.201901223. View

Germain M, Caputo F, Metcalfe S, Tosi G, Spring K, Aslund A . Delivering the power of nanomedicine to patients today. J Control Release. 2020; 326:164-171. PMC: 7362824. DOI: 10.1016/j.jconrel.2020.07.007. View

Wester H, Kessler H . Molecular targeting with peptides or peptide-polymer conjugates: just a question of size?. J Nucl Med. 2005; 46(12):1940-5. View

Johansson A, Lovdal T, Magnusson K, Berg T, Skogh T . Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats. Hepatology. 1996; 24(1):169-75. DOI: 10.1002/hep.510240128. View

10.

Kang L, Jiang D, England C, Barnhart T, Yu B, Rosenkrans Z . ImmunoPET imaging of CD38 in murine lymphoma models using Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018; 45(8):1372-1381. PMC: 5994170. DOI: 10.1007/s00259-018-3941-3. View

11.

Kang L, Jiang D, Ehlerding E, Barnhart T, Ni D, Engle J . Noninvasive Trafficking of Brentuximab Vedotin and PET Imaging of CD30 in Lung Cancer Murine Models. Mol Pharm. 2018; 15(4):1627-1634. PMC: 5920523. DOI: 10.1021/acs.molpharmaceut.7b01168. View

12.

Zuo C, Zou Y, Gao G, Sun L, Yu B, Guo Y . Photothermal combined with intratumoral injection of annonaceous acetogenin nanoparticles for breast cancer therapy. Colloids Surf B Biointerfaces. 2022; 213:112426. DOI: 10.1016/j.colsurfb.2022.112426. View

13.

Zi Y, Yang K, He J, Wu Z, Liu J, Zhang W . Strategies to enhance drug delivery to solid tumors by harnessing the EPR effects and alternative targeting mechanisms. Adv Drug Deliv Rev. 2022; 188:114449. DOI: 10.1016/j.addr.2022.114449. View

14.

Artigas C, Mileva M, Flamen P, Karfis I . Targeted radionuclide therapy: an emerging field in solid tumours. Curr Opin Oncol. 2021; 33(5):493-499. DOI: 10.1097/CCO.0000000000000762. View

15.

Timmermand O, Safi M, Holmqvist B, Strand J . Evaluation of enhanced permeability effect and different linear energy transfer of radionuclides in a prostate cancer xenograft model. Am J Nucl Med Mol Imaging. 2023; 13(4):147-155. PMC: 10509292. View

16.

Ehlerding E, Lacognata S, Jiang D, Ferreira C, Goel S, Hernandez R . Targeting angiogenesis for radioimmunotherapy with a Lu-labeled antibody. Eur J Nucl Med Mol Imaging. 2017; 45(1):123-131. PMC: 5700843. DOI: 10.1007/s00259-017-3793-2. View

17.

Natfji A, Ravishankar D, Osborn H, Greco F . Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection. J Pharm Sci. 2017; 106(11):3179-3187. DOI: 10.1016/j.xphs.2017.06.019. View

18.

Scott A, Tebbutt N, Lee F, Cavicchiolo T, Liu Z, Gill S . A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clin Cancer Res. 2007; 13(11):3286-92. DOI: 10.1158/1078-0432.CCR-07-0284. View

19.

Ghetie V, Ward E . Transcytosis and catabolism of antibody. Immunol Res. 2002; 25(2):97-113. DOI: 10.1385/IR:25:2:097. View

20.

Jiang D, Im H, Sun H, Valdovinos H, England C, Ehlerding E . Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer. Eur J Nucl Med Mol Imaging. 2017; 44(8):1296-1305. PMC: 5471126. DOI: 10.1007/s00259-017-3663-y. View